Evidence map›Paper›PMID 39769007›Full record

ArticleInternational journal of molecular sciences2024

Extracellular Vesicle miR-122-5p as a Prognostic Biomarker in Pediatric Classical Hodgkin Lymphoma.

Rebekka J S Salzmann, Anna Garbin, Enrico Gaffo, Caterina Elia, Gaia Martire, Stefania Bortoluzzi, Annalisa Tondo, Paola Muggeo, Alessandra Sala, Marco Pizzi and 6 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rebekka J S SalzmannIstituto di Ricerca Pediatrica "Città della Speranza", 35128 Padua, Italy.ORCID 0000-0002-1032-4848
Anna GarbinIstituto di Ricerca Pediatrica "Città della Speranza", 35128 Padua, Italy.ORCID 0009-0003-5606-9445
Enrico GaffoDepartment of Molecular Medicine, University of Padua, 35128 Padua, Italy.ORCID 0000-0001-6338-7677
Caterina EliaAYA Oncology Unit, Department of Radiation Oncology, Centro di Riferimento Oncologico IRCCS, 33081 Aviano, Italy.
Gaia MartireIstituto di Ricerca Pediatrica "Città della Speranza", 35128 Padua, Italy.ORCID 0009-0007-8161-3632
Stefania BortoluzziDepartment of Molecular Medicine, University of Padua, 35128 Padua, Italy.ORCID 0000-0001-8240-3070
Annalisa TondoDepartment of Pediatric Oncology and Haematology, Meyer Children's Hospital IRCCS, 50139 Florence, Italy.
Paola MuggeoDepartment of Pediatric Oncology and Hematology, AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, 70124 Bari, Italy.ORCID 0000-0001-8813-3200
Alessandra SalaPediatric Hematology Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.ORCID 0000-0002-6807-9806
Marco PizziPathology Unit, Department of Medicine-DIMED, University of Padua, 35128 Padua, Italy.
Marta PillonMaternal and Child Health Department Pediatric Hematology, Oncology and Stem Cell Transplant Center, University of Padua, 35128 Padua, Italy.ORCID 0000-0002-1190-3198
Elisa CarraroMaternal and Child Health Department Pediatric Hematology, Oncology and Stem Cell Transplant Center, University of Padua, 35128 Padua, Italy.ORCID 0000-0002-6675-867X
Egesta LopciNuclear Medicine Unit, IRCCS-Humanitas Research Hospital, Rozzano, 20089 Milano, Italy.ORCID 0000-0001-9732-1094
Valli de ReImmunopatologia e Biomarcatori Oncologici, CRO Aviano, National Cancer Institute, Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS, 33081 Aviano, Italy.ORCID 0000-0001-6100-9373
Maurizio MascarinAYA Oncology Unit, Department of Radiation Oncology, Centro di Riferimento Oncologico IRCCS, 33081 Aviano, Italy.ORCID 0000-0002-2828-0257
Lara MussolinIstituto di Ricerca Pediatrica "Città della Speranza", 35128 Padua, Italy.ORCID 0000-0003-4802-1866

Funding

Associazione italiana contro le leucemie-linfomi e mieloma IG #2023 #28966Comitato Assistenza Socio-sanitaria in Oncoematologia Pediatrica IG 2017 #20052European Union´s Horizon Europe Marie Skłodowska-Curie Actions Doctoral Networks 101072735MUR PNRR "National Center for Gene Therapy and Drugs based on RNA Technology" CN00000041 CN3 Spoke #6 "RNA chemistry""National Center for HPC, Big Data and Quantum Computing" Project no. CN00000013 CN1 Spoke #8 "In Silico Medicine & Omics Data"
6 · The paper itself

Abstract

Currently, risk stratification for pediatric Hodgkin lymphoma is based on clinical factors such as stage, bulk, and systemic symptoms. Novel minimally invasive biomarkers could enhance both prognosis and treatment strategies. Therefore, the plasma extracellular vesicles' microRNA profile was characterized by small RNA sequencing in 36 classical Hodgkin lymphoma cases and these findings were confirmed in an extended cohort of 86 patients by RT-qPCR. It was found that the levels of miR-122-5p at diagnosis were significantly higher

Indexed as

Biomarkers, TumorExtracellular VesiclesHodgkin DiseaseMicroRNAsAdolescentChildChild, PreschoolFemaleHumansMalePrognosisBiomarkers, TumorMicroRNAsMIRN122 microRNA, humanbiomarkersdiagnosticsextracellular vesiclesHodgkin lymphomaimmune escapeinflammationliquid biopsymiRNArelapseT-cells

Identifiers

PMID39769007
PMCPMC11678363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.